|
Photo placeholder
|
| Affiliations |
University of Nevada, Las Vegas |
| Country |
USA |
| H-index |
190 |
| ORCID |
0000-0001-6396-9390 |
| Research Focus |
[Alzheimer's Disease](/diseases/alzheimers), [Lewy Body Dementia](/diseases/dementia-lewy-body), Clinical Trials |
| Mechanisms |
Cholinergic dysfunction, Drug development, Clinical outcome measures |
Jeffrey Cummings is a renowned neurologist and clinical researcher specializing in Alzheimer's disease and related dementias. He is a leading authority on clinical trials for neurodegenerative diseases and has been instrumental in developing new therapeutic approaches. As director of the Cleveland Clinic Lou Ruvo Center for Brain Health and now at UNLV, Dr. Cummings has led numerous clinical trials and contributed to the development of novel outcome measures for dementia research.1
Recent PubMed-indexed publications (2024-present):
- Cell type-specific gene regulatory atlas prioritizes drug targets and repurposable medicines in Alzheimer's disease. Genome research. 2026.
- Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation. Alzheimer's & dementia (New York, N. Y.). 2026.
- The roles of biomarkers in Alzheimer's disease clinical trials. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2026.
- The role for artificial intelligence in identifying combination therapies for Alzheimer's disease. The journal of prevention of Alzheimer's disease. 2025.
- Add-on combination therapy with monoclonal antibodies: Implications for drug development. The journal of prevention of Alzheimer's disease. 2025.
Dr. Cummings has made fundamental contributions to understanding and treating Alzheimer's disease and related disorders:
- Led over 100 clinical trials for AD and related dementias
- Developed novel outcome measures for dementia trials
- Pioneered trials for disease-modifying therapies
¶ Lewy Body Dementia
- Established diagnostic criteria for DLB
- Investigated cholinergic dysfunction in DLB
- Led trials for DLB treatments
- Contributed to development of cholinesterase inhibitors
- Advocated for combination therapy approaches
- Identified new therapeutic targets
- Characterized behavioral symptoms in dementia
- Developed assessment tools for neuropsychiatric symptoms
- Investigated treatment approaches for agitation and psychosis
- Clinical Trials: Led numerous pivotal AD clinical trials
- Outcome Measures: Developed novel clinical outcome measures
- DLB Research: Established diagnostic criteria and treatment approaches
- Training: Trained generations of dementia researchers
- Cummings JL, et al. "The Neuropsychiatric Inventory: assessing psychopathology in dementia patients." Neurology. 1997;48(5 Suppl 6):S10-S16. PMID: 9153160
- Cummings JL. "Alzheimer's disease." N Engl J Med. 2004;351(1):56-67. PMID: 15229308
- McKeith IG, et al. "Diagnosis and management of dementia with Lewy bodies: third consensus report of the DLB Consortium." Neurology. 2017;89(1):88-100. PMID: 28592453
- Cummings JL. "Lessons learned from Alzheimer disease: clinical trials with novel therapeutic targets." CNS Drugs. 2011;25(5):359-374. PMID: 21443526
- Cummings JL, et al. "Alzheimer's disease: drug development pipeline 2023." Alzheimers Dement. 2023;19(5):2211-2226. PMID: 36971031
¶ Awards and Recognition
- Lifetime Achievement Award, American Neuropsychiatric Association
- Potamkin Prize Nominee
- Distinguished Scientist Award, Sleep Research Society
The study of Jeffrey Cummings has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
flowchart LR
subgraph Focus ["Research Focus"]
F1["Jeffrey Cummings"]
end
subgraph Contributions ["Key Contributions"]
C1["Mechanistic<br>Discovery"]
C2["Therapeutic<br>Target"]
C3["Biomarker<br>Development"]
end
F1 --> C1
F1 --> C2
F1 --> C3
C1 --> Knowledge["Disease<br>Knowledge"]
C2 --> Knowledge
C3 --> Knowledge